Predictive Oncology Inc. (NASDAQ: POAI) Set to Capitalize on Increased AI Usage within Oncological Treatments
Predictive Oncology develops AI-solutions designed to assist clinicians in formulating personalized treatment plans for oncological patients Artificial Intelligence is being increasingly used to help understand and accurately predict how drug therapies can interact with specific patients POAI’s TumorGenesis subsidiary is also creating laboratory-grown tumors to help clinicians and researchers to better test therapies Predictive Oncology (NASDAQ: POAI), a knowledge-driven precision medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, is set to play a key role as the integration of AI technology within cancer care continues to improve the accuracy and…